Clene Nanomedicine Announces Top-Line Results from Phase 2 RESCUE-ALS Clinical Trial
November 02, 2021 07:00 ET
|
Clene Inc.
RESCUE-ALS Phase 2 Trial did not meet primary MUNIX biomarker endpoint or secondary FVC endpoint at week 36; MUNIX efficacy signal was observed at week 12 (p=0.057)MUNIX trial results demonstrated...
Clene Announces Initiation of a Second FDA Expanded Access Program with CNM-Au8 for People Living with Amyotrophic Lateral Sclerosis
September 23, 2021 07:00 ET
|
Clene Inc.
SALT LAKE CITY, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Clene Presents Phase 2 CNM-Au8 CNS Target Engagement Data at the International Parkinson and Movement Disorder Society Virtual Congress 2021
September 17, 2021 07:00 ET
|
Clene Inc.
SALT LAKE CITY, Sept. 17, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Clene Completes Final Patient Visit in Phase 2 RESCUE-ALS Study: Topline Data Readout Expected Q4 2021
September 09, 2021 07:00 ET
|
Clene Inc.
Final patient visit has been completed in its Phase 2 RESCUE-ALS study; study close-out activities have commenced90% of eligible patients are continuing to be treated under a long-term open label...
Clene Nanomedicine to Present at Upcoming Virtual Investor Conferences
August 31, 2021 07:00 ET
|
Clene Inc.
SALT LAKE CITY, Aug. 31, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Clene Enters into Two Leases to Materially Expand Manufacturing Capacity of its Lead Asset CNM-Au8®
August 11, 2021 07:00 ET
|
Clene Inc.
SALT LAKE CITY, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Clene Reports Second Quarter 2021 Operating and Financial Highlights
August 10, 2021 07:00 ET
|
Clene Inc.
Phase 2 REPAIR program demonstrated statistically significant improvements in brain energetic metabolism with CNM-Au8®, a gold nanocrystal suspension Phase 2, placebo-controlled RESCUE-ALS trial...
Clene Nanomedicine Appoints Dr. Vallerie McLaughlin to its Board of Directors
August 05, 2021 16:01 ET
|
Clene Inc.
SALT LAKE CITY, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...
Clene Reports Positive Top-line Results from its Phase 2 REPAIR Clinical Trials in Parkinson’s Disease and Multiple Sclerosis
August 05, 2021 07:00 ET
|
Clene Inc.
Achieved a statistically significant increase in the Phase 2 program’s primary endpoint (mean change in brain NAD+/NADH ratio) CNM-Au8®, a gold nanocrystal suspension, significantly improved...
Clene to Present at Canaccord Genuity's Annual Growth Conference
August 03, 2021 07:00 ET
|
Clene Inc.
SALT LAKE CITY, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ: CLNN) along with its subsidiaries “Clene” and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage...